Author: Ravi Shankar

Växjö, Sweden, 23 October 2026 * * * JLT Mobile Computers, a leading supplier of rugged computers for demanding environments, publishes its interim report for the period January–September 2026 today.

Summary of key figures

	July–Sept		January–Sept
Order Intake, MSEK	15.2 (30.1)		64.9 (111.6)
Net Sales, MSEK	16.9 (28.2)		75.1 (104.0)
Operating Profit, MSEK	-4.5 (1.6)		-5.9 (1.1)
Profit after taxes, MSEK	-4.6 (1.3)		-6.8 (0.9)
Cashflow, MSEK	2.5 (8.1)		-7.2 (2.9)

CEO comments

The period was characterized by weak demand, particularly in our largest segment, warehousing and logistics. This development was primarily attributable to component shortages and sharply higher prices, combined with geopolitical uncertainty and elevated energy costs. In some cases, memory prices increased by as much as 15 times as suppliers prioritized products for AI and server applications. As a result, JLT, like other industry participants, raised prices for its computers. This contributed to more cautious investment decisions and longer sales cycles. At the same time, our growth segments—container ports and construction and mining equipment—remained stable during the first nine months of the year despite the challenging market conditions.

During the quarter, order intake amounted to SEK 15.2 million and net sales to SEK 16.9 million, both significantly below the corresponding period of the prior year. The lower sales volume weighed on earnings, and operating loss amounted to SEK 4.5 million. For the first nine months of the year, order intake totaled SEK 64.9 million, net sales SEK 75.1 million, and operating loss SEK 5.9 million.

At the same time, the gross margin continued to demonstrate resilience. For the first nine months of the year, it was 41.5 percent, compared with 38.0 percent in the corresponding period of 2025. The improvement was primarily driven by a higher share of revenue from service agreements and a favorable currency effect from the stronger U.S. dollar. However, due to the lower sales volume, gross profit was insufficient to cover the cost base.

Cash flow was positive at SEK 2.5 million for the quarter but amounted to negative SEK 7.2 million for the first nine months of the year. At the end of the period, the Group had SEK 9.7 million in cash and cash equivalents, an equity ratio of 54 percent, and no interest-bearing debt. Our financial position provides flexibility, but developments during the year underscore the importance of continued cost and capital discipline.

Our priorities are clear: increase sales activity, expand our partner network, broaden the business into additional application areas, and align the cost base with the lower level of activity. Market uncertainty persists and sales cycles remain long, but the underlying need for reliable, rugged computers is unchanged, particularly in our target segments.

We are working with determination to improve near-term performance while strengthening our long-term position. A competitive product portfolio, a strong gross margin, and an experienced team provide a solid foundation. In the near term, our priorities are to strengthen order intake, protect cash flow, and align the cost base ahead of the fourth quarter and next year.

Per Holmberg, CEO

The full interim report is attached to this press release and available for download at the company’s website, jltmobile.com. Additional financial information is available online on JLT’s investor pages.

This information is information that JLT Mobile Computers AB (pub) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 08:00 am CET on Friday October 23, 2026.

Reader Enquiries JLT Mobile Computers Group	Certified Adviser
Per Holmberg, CEO	Eminova Fondkommission AB
Tel.: +46 70 361 3934	Tel.: +46 08 684 211 10
per.holmberg@jltmobile.com www.jltmobile.com	adviser@eminova.se www.eminova.se

About JLT Mobile Computers

JLT Mobile Computers is a leading supplier of rugged mobile computing devices and solutions for demanding environments. 30 years of development and manufacturing experience have enabled JLT to set the standard in rugged computing, combining outstanding product quality with expert service, support and solutions to ensure trouble-free business operations for customers in warehousing, transportation, manufacturing, mining, ports and agriculture. JLT operates globally from offices in Sweden, France, and the US, complemented by an extensive network of sales partners in local markets. The company was founded in 1994, and the share has been listed on the Nasdaq First North Growth Market stock exchange since 2002 under the symbol JLT. Eminova Fondkommission AB acts as Certified Adviser. Learn more at jltmobile.com.

Attachment

• Interim Report January–September, 2026

• EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses 
• Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress supplementing very convincing two-year data from the trial
• The data will be presented at a poster session on October 24, 2026, followed by a webinar on October 29, 2026, providing further insights into the findings

COPENHAGEN, Denmark, October 23, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year immune and clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma.

The data demonstrates EVX-01 inducing an immune response in all patients, with 89% of its personalised vaccine antigen targets inducing a tumor-specific immune response in treated patients. Further, sustained T-cell responses were observed, with preserved magnitude and breadth of the specific immune response, during the third year of the phase 2 trial in which EVX-01 was administered as monotherapy.

The new data also shows that all patients maintained their clinical response observed at two-year follow-up with no tumor progression observed through the third year of EVX-01 treatment alone. The data will be presented in a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026 held in Madrid, Spain, tomorrow.

The new findings supplement the unprecedented two-year data presented at ESMO in 2025, showing a 75% Objective Response Rate with 25% of patients obtaining a complete response.

“We are delighted to announce yet another set of strong immune and clinical data for EVX-01. The 89% target precision documented in the trial is another confirmation that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. Thus, the new data supports both EVX-01 as a promising personalized cancer vaccine and our platform as a validated technology for discovery and design of novel treatments,” says Birgitte Rønø, CSO and COO of Evaxion.

“What makes these three-year findings particularly compelling is not only the durability of clinical responses, but also the sustained strength and breadth of vaccine-induced T-cell immunity. These results offer an exciting glimpse into the future of precision oncology, where we can harness the unique biology of each patient’s tumor to train the immune system to recognize and target cancer with remarkable specificity. The prospect of translating this highly personalized immune response into long-lasting disease control represents an important step forward and offers renewed hope for patients facing advanced cancer“, says Professor Muhammad Adnan Khattak, Oncology, One Clinical Research, Hollywood Private Hospital & Edith Cowan University, Perth, Australia, key opinion leader and one of the trial’s investigators.

Building on convincing two-year results
In addition to promising response rates, the two-year data from the trial also showed a durable clinical benefit, with 92% of patients still responding at two years of follow-up and no relapses observed.

54% of patients had a deepened response following initiation of EVX-01 treatment, improving from stable disease or partial response to partial or complete response. Tumor reduction (target lesions) was observed in 15 out of the 16 patients enrolled in the trial.

EVX-01 induced an immune response in all patients, with 86% of the vaccine neoantigens generating potent specific T-cell responses as measured at the two-year follow-up. Analyses of additional samples collected during the one-year extension phase further increased this neoantigen hit-rate to 89%.

Evaxion maintains a cash runway extending well into the second half of 2027.

About the phase 2 trial
The phase 2 trial investigated EVX-01 in patients with advanced melanoma. Each patient enrolled in the trial received a unique vaccine designed and manufactured based on their individual biology.

In the first two-years, patients received EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Six out of 12 responders continued in the trial’s one-year extension, where they received EVX-01 as stand-alone therapy.

Webinar on October 29, 2026
Evaxion will host a webinar featuring key opinion leader and trial investigator, Professor Muhammad Adnan Khattak, on October 29, 2026, at 15.30 CET/10.30am EDT.

The webinar can be attended through registration via this link.

In the webinar, Professor Khattak will present the three-year clinical and immune data from the EVX-01 phase 2 trial in patients with advanced melanoma. The presentation will highlight clinical outcomes, durability of responses and vaccine-induced immune responses following three years of follow-up. The presentation will be followed by a Q&A session, with participants encouraged to submit questions.

Poster presentation details

• Poster title: EVX-01, a personalized cancer vaccine, induces sustained T-cell responses and durable disease control in advanced melanoma after three-year of follow-up
• Presentation#: 2006P
• Location: Poster Area – Hall 5
• Topic: Investigational immunotherapy
• Date/Time: October 24, 2026, at 12:00 – 12:45 CET
• Presenter: Professor Muhammad Adnan Khattak, Director, Oncology, One Clinical Research, Hollywood Private Hospital & Edith Cowan University, Perth, WA, Australia

About EVX-01
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors. It is currently being evaluated as a treatment of advanced melanoma and is Evaxion’s lead clinical asset.

Designed with our AI-Immunology™ platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system to fight off cancer by mounting a targeted response against tumor-specific neoantigens.

Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.

We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

ICG Enterprise Trust plc (the “Company”)

23 October 2026

Transaction in Own Shares

The Company announces that on 22 October 2026 it bought back 15,000 of its own shares under the long-term buyback programme, to be held as treasury shares, at an average price of 1363 pence per share.

Further details are set out below:

• Number of shares held as treasury shares following settlement of this purchase: 3,557,500
• Total shares in issue excluding treasury shares following settlement of this purchase: 59,996,692

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2026, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2027), or until expressly revoked by shareholders.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company’s current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company’s general authority to repurchase shares.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 23 October 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares	22 October 2026
Number of Shares purchased	19,549 Class A Shares
Highest price/lowest price paid	£14.94 / £14.83
ISIN for the Shares	GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 36,941,317‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 36,941,317 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

Neuberger Private Equity Partners Limited (“NBPE”) invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger

Neuberger was founded in 1939 to do one thing: deliver compelling investment results for our clients over the long term. This remains our singular purpose today, driven by a culture rooted in deep fundamental research, the pursuit of investment insight and continuous innovation on behalf of clients, and facilitated by the free exchange of ideas across the organization.

From offices in 39 cities[1] across 26 countries, Neuberger manages a range of equity, fixed income, private equity and hedge fund strategies on behalf of institutions, advisors and individual investors worldwide. With more than 780[1] investment professionals and over 2,900[1] employees in total, Neuberger has built a diverse team of individuals united in their commitment to client outcomes and investment excellence. Our culture has afforded us enviable retention rates among our senior investment staff and we are proud to have been ranked 1st by Pensions & Investments in their 2025 “Best Places to Work in Money Management” survey, where we have placed 1st in four of the last five years and finished in the top two for 12 consecutive years[2].

As a private, independent, employee-owned investment manager, Neuberger is structurally aligned with the long-term interests of our clients. We have no external parent or public shareholders to serve, nor other lines of business to distract us from our core mission. And with our employees and their families invested alongside our clients—plus 100% of employee deferred cash compensation directly linked to team and firm strategies—we are truly in this together.
For more information, please visit our website: www.nb.com/en/global/who-we-are.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

[1] Firm data reflects the collective data for the various subsidiaries of Neuberger Berman Group LLC as of 30 June 2026.

[2] Among organizations with over 1,000 employees by Pensions & Investments. For additional information on the criteria for the award, please visit https://www.pionline.com/awards/best-places-to-work-in-money-management/pi-best-places-to-work-2025.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

LEI: 213800NNT42FFIZB1T09 
23 October 2026

Transactions in Own Shares

Foresight Group Holdings Limited (“Foresight”, the “Group”), a leading investment manager in real assets and providing capital for growth, announces that, in accordance with the terms of its current share buyback programme announced on 10 April 2025 (the “Share Buyback”), the Group purchased the following number of its ordinary shares of £nil par value (“Ordinary Shares”) each through JOH Berenberg, Gossler & Co KG (which is trading for these purposes as Berenberg) (“Berenberg”).

Date of purchase:	16 October 2026
Aggregate number of Ordinary Shares purchased:	10,000
Lowest price paid per share (GBp):	444.50
Highest price paid per share (GBp):	448.50
Volume weighted average price paid per share (GBp):	447.165250

Date of purchase:	19 October 2026
Aggregate number of Ordinary Shares purchased:	10,000
Lowest price paid per share (GBp):	443.50
Highest price paid per share (GBp):	446.00
Volume weighted average price paid per share (GBp):	444.519400

Date of purchase:	20 October 2026
Aggregate number of Ordinary Shares purchased:	10,000
Lowest price paid per share (GBp):	437.00
Highest price paid per share (GBp):	448.50
Volume weighted average price paid per share (GBp):	442.316900

Date of purchase:	21 October 2026
Aggregate number of Ordinary Shares purchased:	10,000
Lowest price paid per share (GBp):	446.00
Highest price paid per share (GBp):	450.50
Volume weighted average price paid per share (GBp):	448.680800

Date of purchase:	22 October 2026
Aggregate number of Ordinary Shares purchased:	10,000
Lowest price paid per share (GBp):	449.50
Highest price paid per share (GBp):	456.50
Volume weighted average price paid per share (GBp):	453.564500

Once settled, the purchased shares will be held by the Group in treasury, which means they will have no voting rights while they are held in treasury. Under the current Buyback Programme, an aggregate of 7,728,732 Ordinary Shares have been bought back.

As a result of the above, of the Group’s 112,347,803 Ordinary Shares currently in issue, a total of 11,081,960 have voting rights and 1,265,843 held in treasury and are therefore non-voting. The total number of voting shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in the Group under the FCA’s Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of the UK version of Regulation (EU) No. 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback.

Individual information:

Number of ordinary shares purchased	Transaction price (GBp share)	Time of transaction (UK Time)	Trading Venue
384	445.000	16/10/2026 08:00:23	LSE
384	444.500	16/10/2026 08:17:41	LSE
416	446.000	16/10/2026 08:17:49	LSE
1020	446.500	16/10/2026 08:37:24	LSE
185	446.500	16/10/2026 08:41:40	LSE
195	446.500	16/10/2026 08:42:08	LSE
1764	446.500	16/10/2026 09:00:52	LSE
1881	448.000	16/10/2026 09:05:59	LSE
191	448.000	16/10/2026 09:06:05	LSE
191	448.000	16/10/2026 09:06:10	LSE
1968	447.500	16/10/2026 09:06:42	LSE
1421	448.500	16/10/2026 09:09:48	LSE
378	446.000	19/10/2026 08:00:15	LSE
341	446.000	19/10/2026 08:00:15	LSE
32	444.500	19/10/2026 08:21:17	LSE
189	444.500	19/10/2026 08:34:08	LSE
765	445.000	19/10/2026 08:48:12	LSE
614	445.000	19/10/2026 08:48:12	LSE
207	445.000	19/10/2026 09:46:06	LSE
514	444.500	19/10/2026 09:47:26	LSE
338	443.500	19/10/2026 09:50:33	LSE
189	444.000	19/10/2026 10:12:27	LSE
1700	443.500	19/10/2026 10:13:59	LSE
223	443.500	19/10/2026 10:13:59	LSE
1234	443.500	19/10/2026 10:13:59	LSE
455	444.500	19/10/2026 11:17:32	LSE
1075	445.500	19/10/2026 11:37:26	LSE
189	446.000	19/10/2026 11:40:57	LSE
189	446.000	19/10/2026 12:02:03	LSE
313	445.500	19/10/2026 12:02:51	LSE
255	444.500	19/10/2026 12:58:47	LSE
714	444.500	19/10/2026 12:58:47	LSE
86	444.000	19/10/2026 13:00:04	LSE
189	445.000	20/10/2026 08:18:26	LSE
189	444.500	20/10/2026 08:18:46	LSE
499	444.000	20/10/2026 08:33:23	LSE
229	441.500	20/10/2026 09:26:33	LSE
349	441.500	20/10/2026 09:26:33	LSE
149	439.500	20/10/2026 09:57:53	LSE
262	439.500	20/10/2026 09:57:55	LSE
295	439.500	20/10/2026 09:57:55	LSE
428	440.000	20/10/2026 10:00:03	LSE
276	440.000	20/10/2026 10:00:03	LSE
311	438.000	20/10/2026 10:45:25	LSE
340	438.500	20/10/2026 10:56:55	LSE
1182	440.000	20/10/2026 11:24:38	LSE
276	439.500	20/10/2026 11:41:50	LSE
312	437.500	20/10/2026 13:03:44	LSE
195	437.000	20/10/2026 13:35:15	LSE
312	438.500	20/10/2026 13:57:55	LSE
250	438.000	20/10/2026 13:58:06	LSE
189	438.000	20/10/2026 14:00:40	LSE
572	442.500	20/10/2026 14:43:02	LSE
256	442.000	20/10/2026 14:43:25	LSE
189	445.500	20/10/2026 14:51:27	LSE
383	445.000	20/10/2026 14:52:59	LSE
549	448.500	20/10/2026 15:30:03	LSE
500	448.000	20/10/2026 15:30:09	LSE
965	446.500	20/10/2026 15:30:29	LSE
354	448.500	20/10/2026 15:34:24	LSE
200	450.500	21/10/2026 08:05:40	LSE
573	450.000	21/10/2026 08:09:14	LSE
886	450.000	21/10/2026 08:15:15	LSE
258	449.500	21/10/2026 08:36:13	LSE
270	449.000	21/10/2026 08:41:11	LSE
186	448.500	21/10/2026 08:41:44	LSE
380	448.500	21/10/2026 09:12:57	LSE
228	447.500	21/10/2026 09:23:00	LSE
503	447.500	21/10/2026 09:23:00	LSE
1216	446.000	21/10/2026 09:41:28	LSE
206	447.000	21/10/2026 09:58:28	LSE
128	447.000	21/10/2026 09:58:28	LSE
1757	448.000	21/10/2026 10:06:55	LSE
1361	448.500	21/10/2026 10:14:52	LSE
246	448.500	21/10/2026 10:24:22	LSE
761	450.500	21/10/2026 10:24:48	LSE
200	450.500	21/10/2026 10:24:48	LSE
573	450.500	21/10/2026 08:05:40	LSE
886	450.000	21/10/2026 08:09:14	LSE
258	450.000	21/10/2026 08:15:15	LSE
270	449.500	21/10/2026 08:36:13	LSE
186	449.000	21/10/2026 08:41:11	LSE
380	448.500	21/10/2026 08:41:44	LSE
228	448.500	21/10/2026 09:12:57	LSE
503	447.500	21/10/2026 09:23:00	LSE
1216	447.500	21/10/2026 09:23:00	LSE
206	446.000	21/10/2026 09:41:28	LSE
128	447.000	21/10/2026 09:58:28	LSE
1757	447.000	21/10/2026 09:58:28	LSE
1361	448.000	21/10/2026 10:06:55	LSE
246	448.500	21/10/2026 10:14:52	LSE
761	448.500	21/10/2026 10:24:22	LSE
186	449.500	22/10/2026 08:36:03	LSE
186	449.500	22/10/2026 08:36:08	LSE
745	451.000	22/10/2026 08:57:01	LSE
186	452.500	22/10/2026 09:00:28	LSE
9	452.500	22/10/2026 09:05:00	LSE
177	452.500	22/10/2026 09:05:00	LSE
300	454.000	22/10/2026 09:16:57	LSE
186	453.500	22/10/2026 09:34:32	LSE
206	453.500	22/10/2026 09:34:32	LSE
642	453.500	22/10/2026 09:45:44	LSE
349	453.500	22/10/2026 09:45:44	LSE
100	454.000	22/10/2026 09:53:38	LSE
226	453.000	22/10/2026 10:02:04	LSE
186	453.000	22/10/2026 10:18:20	LSE
186	452.500	22/10/2026 10:20:17	LSE
204	451.500	22/10/2026 10:41:53	LSE
186	453.000	22/10/2026 11:13:45	LSE
189	453.000	22/10/2026 11:15:00	LSE
297	452.500	22/10/2026 11:55:54	LSE
191	452.500	22/10/2026 12:16:48	LSE
255	452.500	22/10/2026 12:16:48	LSE
186	453.000	22/10/2026 13:00:55	LSE
199	453.500	22/10/2026 13:30:20	LSE
352	453.500	22/10/2026 13:45:22	LSE
358	453.500	22/10/2026 13:55:27	LSE
269	453.500	22/10/2026 14:00:33	LSE
85	453.000	22/10/2026 14:13:50	LSE
260	453.000	22/10/2026 14:14:15	LSE
186	453.000	22/10/2026 14:30:32	LSE
188	456.500	22/10/2026 14:59:25	LSE
281	456.000	22/10/2026 15:06:10	LSE
204	456.000	22/10/2026 15:20:04	LSE
400	455.500	22/10/2026 15:26:47	LSE
138	455.500	22/10/2026 15:26:47	LSE
240	455.500	22/10/2026 15:29:09	LSE
400	455.500	22/10/2026 15:29:09	LSE
400	455.500	22/10/2026 15:29:09	LSE
400	455.500	22/10/2026 15:29:09	LSE
262	455.500	22/10/2026 15:29:09	LSE

For further information please contact:

Foresight Group Investors
Ben McGrory
+44 (0) 7443 821577
ir@foresightgroup.eu

Berenberg (Joint Corporate Broker)
James Felix / John Welch / Dan Gee-Summons
+44 (0) 203 753 7800

H-Advisors Maitland
Sam Cartwright / Audrey Da Costa
+44 (0) 782 725 4561 / +44 (0) 781 710 5562
Foresight@h-advisors.global

About Foresight Group Holdings Limited
Founded in 1984, Foresight is a leading investment manager in real assets and capital for growth, operating across the UK, Europe, and Australia.
With decades of experience, Foresight offers investors access to attractive investment opportunities at the forefront of change. Foresight actively builds and grows investment solutions to support the energy transition, decarbonise industry, enhance nature recovery and realise the economic potential of ambitious companies.

A constituent of the FTSE 250 index, Foresight’s diversified investment strategies combine financial and operational skillsets to maximise asset value and provide attractive returns to its investors. Its wide range of private and public funds is complemented with a variety of investment solutions designed for the retail market.

Foresight is united by a shared commitment to build a sustainable future and grow thriving companies and economies.

Visit https://foresight.group for more information.
Follow us on LinkedIn for key updates. 

SATO Corporation, Interim Report 23 October 2026 at 9:00 am EET

This is a summary of SATO’s interim report for January–September, which has been published in full as an appendix to the release and at www.sato.fi/en. The figures in the report are unaudited.

Summary for 1 Jan – 30 Sep 2026 (1 Jan – 30 Sep 2025)

• The economic occupancy rate was 95.5% (95.2).
• Net sales totalled EUR 244.1 million (235.5).
• Net rental income was EUR 169.1 million (166.2).
• Profit before taxes was EUR 69.2 million (80.3).
• The unrealised change in the fair value of investment properties included in the result was EUR -4.1 million (7.3).
• Housing investments amounted to EUR 131.6 million (219.4).
• Invested capital at the end of the review period was EUR 4,945.2 million (4,864.2).
• Return on invested capital was 3.7% (4.0).
• Equity was EUR 2,727.0 million (2,663.3) or EUR 32.12 per share (31.37).
• Earnings per share were EUR 0.65 (0.76).
• A total of 613 rental apartments (968) were acquired.

Summary for 1 Jul – 30 Sep 2026 (1 Jul – 30 Sep 2025)

• The economic occupancy rate was 96.0% (95.8).
• Net sales totalled EUR 82.1 million (80.9).
• Net rental income was EUR 62.1 million (61.9).
• Profit before taxes was EUR 24.2 million (35.1).
• The unrealised change in the fair value of investment properties included in the result was EUR -6.0 million (5.2).
• Housing investments amounted to EUR 14.8 million (207.5).
• Earnings per share were EUR 0.23 (0.33).
• 1 rental apartment (968) was acquired. 

President and CEO Antti Aarnio
SATO’s economic occupancy rate developed positively during the period under review and was 95.5% (95.2) at the end of the period. The improvement in the occupancy rate is primarily driven by strong operational performance, which we are continuously developing.

In summer, B2B sales reached a record-high level. Demand for rental housing has been increased by factors including the ongoing data centre investments particularly in Espoo.

SATO’s average rent per square metre remained unchanged and was EUR 18.51 per m² per month (18.51) at the end of the review period. Net sales increased to EUR 244.1 million (235.5) and net rental income was EUR 169.1 million (166.2).

The number of vacant rental apartments in the Helsinki Metropolitan Area has continued to decrease, but the development is slow and the oversupply in the market persists.

During the summer, we inspected all SATOhome balconies with fibre cement railings. The renovations of the around 1,500 balconies taken out of use as a precautionary measure will be completed by the end of the year.

SATO’s new accounting system was launched successfully on 1 October as the final part of SATO’s major system overhaul.

The general uncertainty in the housing market continued despite the upturn seen in the Finnish economy. Uncertainty about personal finances and the Finnish economy has increased the popularity of rental housing in all income categories.

Antti Aarnio, President and CEO of SATO

Key figures

	1–9/2026	1–9/2025	1–12/2025
Net sales, EUR million	244.1	235.5	316.1
Number of rental apartments, pcs	27,313	26,787	26,786
Investment property, EUR million	5,366.9	5,215.3	5,237.4
Housing investments, EUR million	131.6	219.4	239.8
Average rent at the end of the review period, €/m2/month	18.51	18.51	18.48
Cash earnings (CE), EUR million	64.7	64.3	91.8
Shareholders’ equity, EUR million	2,727.0	2,663.3	2,685.2

Outlook
European and Finnish economic development is governed by geopolitics. The war in the Middle East and its repercussions are slowing down economic growth and accelerating inflation in the euro area. This has kept market rates on an upward trajectory since late February. The Middle East crisis has pushed up the energy prices in particular and, consequently, accelerated inflation. To keep price increases in check, the European Central Bank has raised the deposit facility rate twice in line with market expectations.

The Finnish economy has picked up this year. The autumn interim forecast of the Bank of Finland shows that GDP will increase by 1.7% in 2026 and by 1.6% in 2027. Inflation is projected to be 2.4% this year and fall to 1.4% next year as energy prices will decline. Despite the projected growth, the labour market is recovering slowly and Finland’s general government finances still remain in deficit.

Unemployment and the general uncertainty are still reflected in weak consumer confidence, but business confidence has nevertheless remained above the long-term average.

In its economic outlook published in early October, the Confederation of Finnish Construction Industries (CFCI) forecasts that construction activity will grow by 2% this year and 4% next year. However, growth is uneven: infrastructure and commercial construction are gaining momentum, particularly from data centre projects, while residential construction still remains at a historically low level.

According to CFCI, housing production will continue to decline this year and is not expected to return to growth next year. Investor demand remains low, and publicly subsidised housing production is contracting sharply. Modest growth in non-subsidised owner-occupied housing construction is not enough to offset the decline in other housing starts. However, CFCI believes that the conditions for a recovery are beginning to emerge. Population growth has remained relatively strong, particularly in the Helsinki Metropolitan Area, while the number of owner-occupied and rental apartments available on the market has started to decrease.

Led by the Ministry of Finance, the group on economic trends in construction estimated in September that there will be no growth in housing starts in 2026. Recovery is expected to begin next year as the oversupply will gradually decline.

The number of vacant apartments in the Helsinki Metropolitan Area has continued to decline. However, progress remains slow, and the oversupply of rental homes and the intense competition for good tenants will continue. The imbalance between supply and demand will not enable any large-scale commencement of newbuild rental housing construction or rent increases reflecting rising costs.

In the years ahead, the imbalance in the rental housing market will be corrected when state-subsidised housing production decreases. According to the forecast by the CFCI, construction starts for subsidised apartment buildings will fall to around 3,000 apartments in 2027, compared with more than 9,000 in 2024.

According to Statistics Finland’s October figures, 1.04 million households lived in rental homes at the end of 2025, an increase of 11,000 from the previous year. Over the past ten years, the number of households living in rental homes has grown by around 200,000. The largest increase in absolute terms has been among households where the oldest member is aged 30 or over. In total, 1.6 million people lived in rental homes at the end of 2025.

The attractiveness of rental housing is increased by changes in the population’s life situations, mobility of work, and economic uncertainty. In addition, the high interest rate level and general economic uncertainty reduce willingness for large investments related to owner-occupied housing. The convenience and flexibility of rental housing are emphasised among young adults in particular.

It is important to continue urban development and land use planning that support diverse housing options. This will help ensure that growth centres will meet the residents’ diverse needs in the future, too.

In line with its majority shareholder’s operating model, SATO Corporation will not publish guidance on its 2026 earnings. The parent company of Balder Finska Otas AB is Fastighets AB Balder, which is quoted on the Stockholm Stock Exchange.

For more information, please contact:
CEO Antti Aarnio, tel. +358 20 134 4200, antti.aarnio@sato.fi
CFO Markku Honkasalo, tel. +358 20 134 4226, markku.honkasalo@sato.fi

Enclosures
Interim Report 1 January to 30 September 2026
Interim Report presentation 1 January to 30 September 2026

Distribution
Euronext Dublin, main media, www.sato.fi/en

SATO Corporation

SATO Corporation is an expert in sustainable rental housing and one of Finland’s largest rental housing providers. SATO owns nearly 27,500 rental homes in the Helsinki Metropolitan Area, Tampere and Turku.

SATO aims to provide excellent customer experience and a comprehensive range of urban rental housing alternatives with good access to public transport and services.

SATO invests profitably, responsibly and with a long-term view. We increase the value of our assets through investments, divestments and repairs. In 2025 SATO celebrated its 85^th anniversary. www.sato.fi/en

Attachments

• SATO Interim Report Q3 2026
• SATO presentation material Q3 2026

Organic growth of 2.0% in Q3

2026 organic growth guidance updated
Acceleration of Horizons deployment

Paris, 23 October 2026 – Ipsos, one of the world’s leading market research and opinion polling companies, generated revenue of €636.2 million in Q3. Organic growth reached 2.0% in the quarter, compared with 0.8% in the first half, driven notably by good performances in EMEA, China and our Citizens business.

For the first nine months of the year, revenue increased by 0.9%, with organic growth reaching 1.2%. Scope effects contributed 1.6%, reflecting the acquisition of The BVA Family, partially offset by the deconsolidation of Russia. Currency effects stood at -1.9%, primarily due to the appreciation of the euro against the US dollar.

	2026 Revenue in € million	2025 Revenue in € million	Total growth	Organic growth
1st quarter	554.9	568.5	-2.4%	-1.4%
2nd quarter	615.2	586.6	4.9%	3.0%
3rd quarter	636.2	635.9	0.0%	2.0%
Revenue	1,806.3	1,791.0	0.9%	1.2%

Organic growth in the order book, for the share of revenue expected to be recognized in 2026, reached 2.0% in Q3 and 1.2% for the first nine months of the year.

The quarter was also marked by the appointment of Kelly Beaver as Chief Executive Officer of Ipsos. She has reaffirmed the Horizons strategic plan, with a clear priority on accelerating its execution. Since her appointment on 30 July, the Group has notably:

• strengthened leadership in execution of the Horizons programme delivery around Globally Managed Services, organizational deployment of AI, and Technology,
• entered into a strategic partnership with Google Cloud to deploy agentic artificial intelligence at scale across the Group and further enhance innovation, automation and the speed of execution of our studies;
• launched a programme promoting the prioritised use of Ipsos.Digital, our end-to-end digital research platform, across a wide range of studies, with the aim of accelerating their execution and delivery;
• expanded its portfolio with the launch of new AI-powered solutions, across more markets.

PERFORMANCE BY REGION

	9 months			Q3
	Revenue in € million	Total growth	Organic growth	Organic growth
EMEA	897.3	2.8%	1.6%	3.5%
Americas	618.2	-1.9%	0.0%	-1.2%
Asia-Pacific	290.8	1.0%	2.8%	4.3%
Total	1,806.3	0.9%	1.2%	2.0%

In EMEA, organic growth reached 3.5% in the third quarter and 1.6% over the first nine months of the year. The Middle East, historically a growth region, has been adversely affected by the ongoing conflict, resulting in a decline in activity. Western Europe, Central and Eastern Europe, and Africa all recorded growth. Total revenue increased by 2.8% at the end of September. This performance benefited from the full-year impact of the integration of The BVA Family, offset by the deconsolidation of the Group’s Russian subsidiary as of January 1, 2026.

In the Americas, organic growth was down 1.2% in the third quarter and was stable over the first nine months of the year. Our results remain below our expectations, mainly reflecting delays in the execution of the Horizons strategic plan in the first half of 2026.

In Asia-Pacific, organic growth reached 4.3% in the third quarter and 2.8% over the first nine months of the year. Good performance in China continues, supported by momentum among both large local and international clients, as well as the success of new AI-enabled offerings. India also contributed to the acceleration of growth in the region.

PERFORMANCE BY AUDIENCE

	9 months			Q3
	Revenue in € million	Total growth	Organic growth	Organic growth
Consumers1	870.2	-1.3%	0.9%	0.7%
Clients & Employees2	370.6	2.9%	-1.1%	-2.5%
Citizens3	308.6	8.2%	4.7%	8.6%
Doctors & Patients4	256.8	-2.8%	1.6%	5.7%
Total	1,806.3	0.9%	1.2%	2.0%

Breakdown of Service Lines by audience segment:
1- Brand Health Tracking, Creative Excellence, Innovation, Ipsos UU, Ipsos MMA, Market Strategy & Understanding, Observer (excl. public sector), Ipsos Synthesio, Strategy3
2- Automotive & Mobility Development, Audience Measurement, Customer Experience, Channel Performance (Mystery Shopping and Shopper), Media Development, ERM, Capabilities
3- Public Affairs, Corporate Reputation
4- Pharma (quantitative and qualitative)

Our service lines dedicated to Consumers and Clients & Employees recorded organic growth of 0.7% and -2.5%, respectively, in Q3, and 0.9% and -1.1% over the first nine months of 2026. Activity was notably driven by our innovation and marketing spend optimization solutions, while certain businesses that experienced good growth last year, notably advertising campaign measurement, faced a particularly demanding comparison base.

Our activities serving Citizens achieved organic growth of 8.6% in Q3 and 4.7% over the first nine months of 2026. Contract wins secured since March, particularly multi-year agreements, support the recovery in activity and demonstrate renewed interest from both public and private decision-makers in gaining a deeper understanding of citizens. Ipsos believes that understanding citizens is a core component of its business and benefits from a unique position to deliver this expertise at scale across the markets in which it operates.

Business among Doctors and Patients continued to accelerate, with organic growth reaching 5.7% in the third quarter. This growth is supported by a positive market environment, characterized by an increase in new drug approvals in the United States and sustained pharmaceutical innovation, both driving demand for market research.

Finally, our Ipsos.Digital DIY platform delivered 14% organic growth. The platform continues to expand its capabilities, including AI-powered features, synthetic respondents and new solutions. As part of our Speed program, which aims to deliver the majority of research projects in less than 48 hours, Ipsos also intends to accelerate the use of the Ipsos.Digital platform within the Group.

OUTLOOK

Given performance over the first nine months of the year and the level of the order book at the end of September, the Group has revised its organic growth outlook for full-year 2026 to between 1.2% and 1.5%, compared with 0.6% in 2025. This outlook also takes into account a persistently uncertain macroeconomic and geopolitical environment, notably marked by the impact of the conflict in the Middle East on the Group’s activities in the region.

The Group confirms its objective of achieving an operating margin rate in line with 2025, reflecting its ability to maintain rigorous financial discipline while continuing to make the investments required to execute its Horizons strategic plan.

ABOUT IPSOS

Ipsos is one of the largest market research companies in the world, present in 90 markets and employing nearly 20,000 people.

Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.

“Game Changers” – our tagline – summarises our ambition to help our 5,000 clients navigate with confidence our world of rapid change.

Founded in France in 1975, Ipsos has been listed on the Euronext Paris since 1 July 1999. The company is part of the SBF 120, Mid-60 indices and is eligible for the Deferred Settlement Service (SRD).
ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP
www.ipsos.com

35 rue du Val de Marne
75 628 Paris, Cedex 13 France
Tel. +33 1 41 98 90 00

Attachment

• Press Release – Third Quarter Results – 231026 – EN – Final version

Bank of Åland Plc
Financial Calendar
October 23, 2026, 8.30 EEST

Financial information and Annual General Meeting, 2027

Year-end Report and Annual Report for 2026

• Year-end Report for 2026: Friday, February 5, 2027
• Annual Report for 2026: Thursday, February 25, 2027

Interim Reports, 2027

• Interim Report for January–March: Monday, April 26, 2027 
• Half-Year Financial Report for January–June: Monday, July 19, 2027
• Interim Report for January–September: Tuesday, October 26, 2027

Annual General Meeting, 2027

• The Annual General Meeting: Wednesday, March 31, 2027

Further information is available from Peter Wiklöf, Managing Director and Chief Executive, tel. +358 40 512 7505

Stock exchange release, inside information

23 October 2026, at 8:10 AM

eQ Plc is renewing its management structure and the composition of its Management Team to strengthen the implementation of its strategy and clarify management roles. Group CEO Jouko Pölönen has been appointed to lead eQ Group’s asset management business and as CEO of eQ Asset Management Ltd as of 23 October 2026. Tero Estovirta, the current CEO of eQ Asset Management Ltd, will leave the company, and the heads of the asset management business areas will join the Group’s Management Team and report directly to the CEO.

The changes to the management structure and the composition of the Management Team will strengthen the implementation of the 2030 growth strategy, accelerate decision-making and bring the heads of the asset management business areas and fund administration into the Group’s Management Team. The acquisition of Genesta Property Nordic AB, signed today, is expected to further strengthen eQ’s platform for international growth and expand its real estate asset management operations into a Nordic business.

• Pertti Vanhanen, who is responsible for eQ’s International Business, Customer Relations and Sales, will be responsible for the integration of Genesta and international real estate investments. Jennifer Eloheimo will continue to be responsible for the Real Estate business in Finland. I would therefore like to welcome Jennifer, as well as Staffan Jåfs, who heads Private Equity, Veli-Pekka Heikkinen, who heads Equity and Fixed Income, and Annamaija Peltonen, who heads Fund Administration, to the Group’s Management Team, says Jouko Pölönen, CEO of eQ Group.
• I would also like to warmly thank Tero for his excellent work and commitment to eQ’s asset management business. Tero has played a key role in building eQ into Finland’s leading real estate asset manager and trusted asset management partner. This provides a solid foundation for the international expansion of our Private Markets business, Pölönen continues.
• I see the organisational changes as the right and natural next step in eQ’s development. I appreciate being offered the opportunity to continue with the company under the new structure, but I have decided to pursue new opportunities. My more than 12 years at eQ have been an exceptionally rewarding journey. I have had the opportunity to work with outstanding clients, colleagues and partners. I leave eQ confident in the company’s future. I would like to extend my warm thanks to all our clients, colleagues and partners for these years together, says Tero Estovirta.

Following the changes, all eQ’s operational activities will be represented in the same Management Team. The composition of eQ’s Management Team as of 23 October 2026 will be:

Jouko Pölönen, CEO of eQ Plc and Managing Director of eQ Asset Management Ltd, M.Sc. (Econ.), eMBA (born 1970)
Jacob af Forselles, Managing Director of Advium Corporate Finance Ltd, M.Sc. (Econ.), LL.M. (born 1973)
Kirsi Hokka, Customer Relations and Sales, Finland, M.Sc. (Econ.) (born 1965)
Pertti Vanhanen, International Business, Customer Relations and Sales, eMBA (born 1962)
Staffan Jåfs, Private Equity, M.Sc. (Econ.) (born 1974)
Jennifer Eloheimo, Real Estate, Finland, LL.M. (born 1980)
Veli-Pekka Heikkinen, Equity and Fixed Income, D.Sc. (Econ.) (born 1968)
Annamaija Peltonen, Managing Director of eQ Fund Management Company Ltd, Vocational Qualification in Business (born 1964)
Antti Lyytikäinen, Finance and Risk Management, M.Sc. (Econ.) (born 1981)
Taina Kyllönen, Human Resources and Communications, M.Sc. (Econ.) (born 1967)
Arimo Leppä, Technology and Development, LL.M. (born 1984)
Juha Surve, Legal and Compliance, LL.M., M.Sc. (Econ.) (born 1980)

Helsinki, 23 October 2026

eQ Plc

Additional information:

Jouko Pölönen, CEO of eQ, tel. +358 50 1282
Taina Kyllönen, Chief HR and Communications Officer, tel. +358 40 5822175

Distribution: Nasdaq Helsinki, www.eQ.fi, key media outlets

eQ is a Finnish group that concentrates on asset management and Corporate Finance business. eQ Asset Management offers a wide range of asset management services to both institutions and individuals. The assets managed by the Group total EUR 13,9 billion. Advium Corporate Finance, which is part of the Group, offers services related to mergers and acquisitions, real estate transactions and equity capital markets. The parent company eQ Plc’s shares are listed on Nasdaq Helsinki. More information about the Group is available on our website www.eQ.fi.

Louvain-la-Neuve, Belgium, October 23, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, announced today that it has signed a contract with an undisclosed customer  for the delivery of a fully integrated Be Efficient electron beam (E-beam) sterilization solution to be installed in Germany.

IBA E-beam technologies enable various industries to be significantly more resilient and environmentally friendly by avoiding toxic chemicals and radioactive materials, and their associated waste, safety issues and hazards. Primarily driven by the conversion of a product portfolio from EtO to E-beam sterilization, this investment marks an important step in accelerating the adoption of IBA’s E-beam technology and the transition towards cleaner, more sustainable sterilization solutions with no chemical residues or emissions.

Designed as a fully automated, next-generation facility, the solution will enable very high throughput for the sterilization of medical products while supporting high operational efficiency and low operating costs. Its integrated design will provide the customer with a streamlined, flexible and scalable platform for advanced electron beam sterilization. The company expects to start sterilization activities with the Be efficient solution in 2029.

The Be Efficient solution will combine IBA’s Rhodotron^® accelerator technology with a comprehensive conveyor system (Product Handling System – PHS), a Beagle® production line control system (PCS), and an integrated building safety system. IBA will provide the complete project scope, encompassing design and engineering, project management, manufacturing, installation, commissioning, and training.

Thomas Servais, President of IBA Industrial Solutions, commented: “Securing this contract is a significant achievement for IBA Industrial Solutions and a strong endorsement of our technology, expertise, and long-term vision. By providing a complete integrated solution, from design and engineering through installation, commissioning, and training, we are helping one of the world’s most respected healthcare industry players enhance its sterilization capabilities with a highly automated, next-generation facility. This project combines exceptional throughput, operational efficiency, and reduced operating costs, setting a new benchmark for performance and reinforcing IBA’s leadership in advanced electron beam sterilization solutions.”

The typical price for a Be-Efficient irradiation solution ranges from € 11 million to EUR 18 million depending on the configuration and options.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

CONTACTS
Thomas Pevenage
Investor Relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability
+32 10 475 890
communication@iba-group.com

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

Attachment

• 261005-IBA-Braun-Be-Efficient-EN-final